Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status.

O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, Leahy AL, Kelly CJ, Agha A, Thompson CJ, O'Gorman DJ, Fitzgerald P, Smith D.

Thromb Res. 2010 Dec;126(6):e423-7. doi: 10.1016/j.thromres.2010.09.003. Epub 2010 Oct 6.

PMID:
20932553
2.

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G.

Am J Pathol. 2006 Dec;169(6):2236-44.

3.

Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.

O'Sullivan EP, Ashley DT, Davenport C, Devlin N, Crowley R, Agha A, Thompson CJ, O'Gorman D, Smith D.

Diabetes Metab Res Rev. 2010 Sep;26(6):496-502. doi: 10.1002/dmrr.1109.

PMID:
20809534
4.

Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.

Nybo M, Poulsen MK, Grauslund J, Henriksen JE, Rasmussen LM.

Diabet Med. 2010 Mar;27(3):289-94. doi: 10.1111/j.1464-5491.2010.02940.x.

PMID:
20536491
5.

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.

Anand DV, Lahiri A, Lim E, Hopkins D, Corder R.

J Am Coll Cardiol. 2006 May 2;47(9):1850-7. Epub 2006 Apr 19.

6.

Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.

Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Høilund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE.

Cardiovasc Diabetol. 2011 Aug 12;10:76. doi: 10.1186/1475-2840-10-76.

7.

Vascular calcification biomarkers and peripheral arterial disease.

Kapetanios D, Karkos C, Giagtzidis I, Papazoglou K, Kiroplastis K, Spyridis C.

Int Angiol. 2016 Oct;35(5):455-9. Epub 2015 Jun 5. Review.

PMID:
26044839
8.

Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.

Niu Y, Zhang W, Yang Z, Li X, Wen J, Wang S, Zhang H, Wang X, Zhou H, Fang W, Qin L, Su Q.

BMC Cardiovasc Disord. 2015 Aug 11;15:86. doi: 10.1186/s12872-015-0079-0.

9.

Osteoprotegerin as a marker of atherosclerosis: a systematic update.

Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H.

Scand Cardiovasc J. 2012 Aug;46(4):203-11. doi: 10.3109/14017431.2012.685491. Epub 2012 May 8. Review.

PMID:
22506827
10.

Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects.

Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, Unt E, Lieberg J, Kals J.

Am J Hypertens. 2010 Jun;23(6):586-91. doi: 10.1038/ajh.2010.38. Epub 2010 Mar 11.

PMID:
20224558
11.

Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women.

Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z.

Metabolism. 2010 May;59(5):742-7. doi: 10.1016/j.metabol.2009.09.019. Epub 2009 Nov 18.

PMID:
19922962
12.

Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease.

Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, Koppensteiner R, Schernthaner GH.

Diabetes Care. 2011 Jan;34(1):156-61. doi: 10.2337/dc10-0788. Epub 2010 Oct 7.

13.

Association between hemoglobin A1c, carotid atherosclerosis, arterial stiffness, and peripheral arterial disease in Korean type 2 diabetic patients.

Choi SW, Shin MH, Yun WJ, Kim HY, Lee YH, Kweon SS, Rhee JA, Choi JS.

J Diabetes Complications. 2011 Jan-Feb;25(1):7-13. doi: 10.1016/j.jdiacomp.2009.12.001. Epub 2010 Jan 27.

PMID:
20106681
14.

Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes.

Mori K, Jono S, Emoto M, Kawagishi T, Yasumoto H, Konishi T, Furumitsu Y, Shioi A, Shoji T, Inaba M, Nishizawa Y.

Angiology. 2010 Feb-Mar;61(1):86-91. doi: 10.1177/0003319708330525. Epub 2009 Jan 14.

PMID:
19147525
15.

Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.

Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, Kucukardali Y, Ipcioglu O, Cagiltay E, Oktenli C, Ozata M.

Exp Clin Endocrinol Diabetes. 2009 Mar;117(3):119-23. doi: 10.1055/s-0028-1085425. Epub 2008 Dec 3.

PMID:
19053023
16.

Elevated osteopontin levels in patients with peripheral arterial disease.

Koshikawa M, Aizawa K, Kasai H, Izawa A, Tomita T, Kumazaki S, Tsutsui H, Koyama J, Shimodaira S, Takahashi M, Ikeda U.

Angiology. 2009 Feb-Mar;60(1):42-5. doi: 10.1177/0003319708314250. Epub 2008 Apr 2.

PMID:
18388057
17.

High circulating osteoprotegerin levels are associated with non-zero blood groups.

Nagy EE, Varga-Fekete T, Puskas A, Kelemen P, Brassai Z, Szekeres-Csiki K, Gombos T, Csanyi MC, Harsfalvi J.

BMC Cardiovasc Disord. 2016 May 26;16(1):106. doi: 10.1186/s12872-016-0287-2.

18.

Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.

Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Suliman ME.

J Nephrol. 2009 Nov-Dec;22(6):774-82.

PMID:
19967657
19.

A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients.

Morena M, Dupuy AM, Jaussent I, Vernhet H, Gahide G, Klouche K, Bargnoux AS, Delcourt C, Canaud B, Cristol JP.

Nephrol Dial Transplant. 2009 Nov;24(11):3389-97. doi: 10.1093/ndt/gfp301. Epub 2009 Jul 2.

PMID:
19574342
20.

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM.

Arthritis Rheum. 2007 Mar;56(3):977-83.

Supplemental Content

Support Center